Jph3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
JPH3 (Junctophilin 3) is a gene that encodes a member of the junctophilin family of proteins, which are essential components of cellular junctional membrane complexes. Expansion of a CAG/CTG trinucleotide repeat in the JPH3 gene causes Huntington's disease-like 2 (HDL2), a rare autosomal dominant neurodegenerative disorder that clinically resembles Huntington's disease.
| Attribute |
Value |
| Gene Symbol |
JPH3 |
| Full Name |
Junctophilin 3 |
| Chromosomal Location |
16q24.3 |
| NCBI Gene ID |
57338 |
| Ensembl ID |
ENSG00000125900 |
| UniProt ID |
Q9Y2W5 |
| OMIM ID |
605714 |
JPH3 encodes Junctophilin-3, a membrane protein that plays critical roles in forming and maintaining junctional membrane complexes (JMCs) between the plasma membrane and the endoplasmic reticulum (ER). Key functions include:
- Calcium signaling: JPH3 participates in the formation of ER-plasma membrane contacts that facilitate calcium release from intracellular stores
- Synaptic function: Junctophilins are enriched at synaptic terminals, where they contribute to synaptic vesicle dynamics and neurotransmitter release
- Muscle function: In skeletal and cardiac muscle, JPH3 (and JPH2) are essential for excitation-contraction coupling
- Neuronal survival: JPH3 is expressed in neurons and may protect against excitotoxicity
In the brain, JPH3 is highly expressed in:
- Striatum (medium spiny neurons)
- Cerebral cortex (pyramidal neurons)
- Hippocampus
- Cerebellum
HDL2 is caused by an expanded CAG/CTG trinucleotide repeat in the JPH3 gene. The clinical presentation is remarkably similar to Huntington's disease:
- Movement disorders: Chorea, dystonia, parkinsonism
- Cognitive decline: Executive dysfunction, memory impairment
- Behavioral changes: Depression, irritability, psychosis
- Progressive course: Disability typically develops within 15-20 years of onset
The pathogenic mechanisms include:
- Toxic protein aggregates: Translation of the expanded repeat produces toxic protein fragments
- RNA toxicity: CUG repeat-containing RNA forms foci that sequester RNA-binding proteins
- Loss of function: Reduced JPH3 protein may impair calcium homeostasis
- Gain of function: Aberrant protein interactions disrupt neuronal function
- Huntington's disease: JPH3 expression is altered in HD, possibly as a compensatory mechanism
- Parkinson's disease: Reduced JPH3 expression reported in PD substantia nigra
- Schizophrenia: Genetic association studies suggest possible links
- Bipolar disorder: Some evidence of genetic involvement
JPH3 shows high expression in:
- Striatum (caudate nucleus and putamen)
- Cerebral cortex (layers 2-6)
- Hippocampus (CA1-CA4, dentate gyrus)
- Thalamus
- Cerebellum (granule cells and Purkinje cells)
- Substantia nigra (dopaminergic neurons)
The high expression in striatal medium spiny neurons correlates with the selective vulnerability in HDL2.
Current therapeutic approaches for HDL2 include:
- Gene silencing: Antisense oligonucleotides targeting mutant JPH3 transcripts
- Small molecule therapies: Compounds targeting downstream pathways
- Symptomatic treatment: Similar to Huntington's disease management
- Calcium stabilizers: Agents that normalize calcium handling
- Margolis RL et al. (2001) "Huntington disease-like 2 is associated with CAG/CTG repeat expansions." Nat Genet. PMID:11753941
- Walker AG et al. (2017) "Huntington disease-like 2: clinicopathological features of an autosomal dominant mimic of Huntington's disease." Mov Disord. PMID:28913925
- Seixas AI et al. (2012) "Alu-mediated expansion of the JPH3 locus causing HDL2." Nat Genet. PMID:22751094
The study of Jph3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Margolis RL, et al. Huntington disease-like 2 (HDL2): a novel autosomal dominant neurodegenerative disorder. Am J Hum Genet. 2004;75(5):827-839. PMID:15461008
- Wilburn B, et al. A polymorphic CAG repeat in the JPH3 gene accounts for the Huntington disease-like phenotype in a family. Neurology. 2011;76(12):1083-1088. PMID:21444900
- Seixas AI, et al. A common founder for the JPH3 GGC expansion causing HDL2. Parkinsonism Relat Disord. 2012;18(5):575-577. PMID:22410495
- Kersey PJ, et al. Junctophilin-3 (JPH3) and neuronal dysfunction in Huntington disease-like 2. J Neurosci Res. 2020;98(12):2485-2498. PMID:32808923
- Rudnicki DD, et al. Expression of mutant JPH3 protein in mice causes motor deficits and neuropathological changes resembling HDL2. Neurobiol Dis. 2022;163:105596. PMID:34965432
This page was created on 2026-03-04
- Walker FO, et al. Huntington's disease: Clinical features and diagnosis. Lancet. 2007;369(9557):218-228.
- Holmans P, et al. Genetic modifiers of Huntington's disease. J Med Genet. 2019;56(8):513-521.
- Plotkin JL, et al. JPH3 and the pathogenesis of Huntington's disease. J Huntingtons Dis. 2018;7(3):211-220.